The company has reorganized the operations of its immune profiler platform, which uses molecular profiling for drug development, a Verily spokesperson told Becker’s.
“This move is aligned with our portfolio reprioritization announced last year, as Verily invests its resources to accelerate solutions that bridge the gap between care delivery and clinical research,” the spokesperson emailed March 25. “This was a difficult decision to make, but that we believe will best enable us to deliver on our precision health promise.”
Verily had previously laid off an unknown number of employees in October. The most recent round of job cuts was first reported by Business Insider.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.